MARIETTA, Ga., Feb. 3, 2017 /PRNewswire/ — MiMedx Group, Inc. MDXG 2.31%, the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, commented today regarding […]
MiMedx Comments On FDA Decision Not To Finalize HCT/P Guidance Documents This Year
MARIETTA, Ga., Feb. 3, 2017 /PRNewswire/ — MiMedx Group, Inc. MDXG 2.31%, the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, commented today regarding […]
Previous post
THE OLD MUTUAL GLOBAL INVESTORS UK LTD. INVESTS $901,000 IN ANIKA THERAPEUTICS INC. (ANIK)Next post
EOI Announces that Dr. Henry Ruiz is the First to Implant the FLXfit™ 3D Expandable Cage in Alabama